<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute exacerbations of idiopathic pulmonary fibrosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute exacerbations of idiopathic pulmonary fibrosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute exacerbations of idiopathic pulmonary fibrosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynn M Schnapp, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy Whelan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3409865980">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease without a clear etiology. Peripheral and basal predominant pulmonary fibrosis with histopathologic and/or computed tomography (CT) findings consistent with usual interstitial pneumonia (UIP) are diagnostic of the disease. Patients with IPF have a poor prognosis: multiple retrospective series demonstrate a median survival of two to three years from diagnosis [
         <a href="#rid1">
          1-5
         </a>
         ]. However, data from clinical trials indicate this may be an underestimate of the true median survival [
         <a href="#rid6">
          6-10
         </a>
         ]. Regardless, the individual clinical course is quite variable; some individuals have stable or slow progression, others demonstrate rapid progression, and still others develop episodic acute declines in lung function, known as "acute exacerbations" (AE) of IPF (AE-IPF)  (
         <a class="graphic graphic_figure graphicRef111393" href="/z/d/graphic/111393.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The following questions will be discussed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         How often does AE occur and what are the potential triggers?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What are the presenting signs and symptoms of an AE?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What are the current recommendations for evaluation and management of AE-IPF?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What are typical outcomes for those who have an AE?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What are the future directions for research in AE?
        </p>
        <p>
        </p>
        <p>
         The risk factors, clinical manifestations, evaluation, diagnosis, and management of AE-IPF will be reviewed here. The clinical manifestations, diagnosis, and management of IPF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H401720513">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact definition of AE-IPF is a work in progress. In 2007, the Idiopathic Pulmonary Fibrosis Network (IPFnet) proposed a definition to better delineate a particular subset of these acute declines in function [
         <a href="#rid11">
          11
         </a>
         ]. A revised "conceptual framework" was proposed by an international working group in 2016 [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The 2007 proposed definition of an "acute exacerbation" (AE) of IPF included all of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A previous or concurrent diagnosis of IPF
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deterioration within 30 days
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New bilateral ground glass opacities and/or consolidation on a background of reticular or honeycomb pattern consistent with usual interstitial pneumonia (UIP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No evidence of pulmonary infection by endotracheal aspiration or bronchoalveolar lavage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of alternative causes including left heart failure, pulmonary embolism, or an identifiable cause of acute lung injury
        </p>
        <p>
        </p>
        <p>
         The 2016 revised criteria more accurately reflect today's knowledge of AE-IPF and should allow for better insights into the etiology, treatment, and outcomes of this process [
         <a href="#rid12">
          12
         </a>
         ]. Similar to the definition in 2007, this newly proposed framework defines an AE as "an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality," but does not set an exact 30 day limit for symptom onset and does not require exclusion of infection. The following diagnostic criteria are proposed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A known diagnosis of IPF (diagnosis may be made at the time of acute respiratory deterioration)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute worsening, "typically less than one month's duration"
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT of the chest with new bilateral ground glass opacification and/or consolidation superimposed on a background of findings consistent with usual interstitial pneumonia (bibasilar reticular opacities associated with honeycomb changes and traction bronchiectasis) (see
         <a class="local">
          'Imaging'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart failure or fluid overload does not fully explain the worsening.
        </p>
        <p>
        </p>
        <p>
         Based on our understanding that these events may be triggered similar to acute lung injury in the non-IPF patient population, events are further classified into "triggered" (ie, postprocedure, drug toxicity, infection, aspiration) versus "idiopathic" (ie, no inciting event identified). This new classification will allow for a more complete picture of these patients.
        </p>
        <p class="headingAnchor" id="H257415247">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Understanding the precise epidemiology has been problematic due to differences in diagnostic criteria, patient populations, baseline disease severity, follow-up time, and statistical methodology. Retrospective cohorts typically report a higher incidence and prevalence and may be hampered by bias to over-report acute deteriorations with a known cause (eg, pulmonary embolism, heart failure) as an AE-IPF [
         <a href="#rid13">
          13
         </a>
         ]. Prospective trials, on the other hand, may have missing data hampering accurate diagnosis of an AE [
         <a href="#rid14">
          14
         </a>
         ], as well as differing prevalence when reported by central reviewers versus the principal investigators [
         <a href="#rid8">
          8,15
         </a>
         ]. A meta-analysis of seven multicenter prospective trials described an overall rate of 26.3 per 1000 patient-years (range of 8.9 to 206.3 per 1000 patients-years) [
         <a href="#rid16">
          16
         </a>
         ]. As prospective clinical trials often exclude patients with advanced disease and comorbidities and as the risk of AE increases with severity of IPF, true rates of AE may be higher than the estimate from prospective trials.
        </p>
        <p class="headingAnchor" id="H1455056404">
         <span class="h1">
          PATHOPHYSIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While our current understanding of the pathophysiology of AE-IPF is limited, AE has clinical similarities to acute respiratory distress syndrome (ARDS). Both have increased oxygen needs, bilateral ground glass opacities and/or consolidation on imaging, and histopathology demonstrating diffuse alveolar damage [
         <a href="#rid17">
          17-20
         </a>
         ]. We know that there are multiple causes for ARDS and it is likely the same for those with AE-IPF. Further, IPF patients likely have maladaptive responses to lung injury, demonstrated by altered responses of IPF versus control fibroblasts to stimuli in vitro [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         There are multiple examples of lung injury that subsequently develop into an AE-IPF [
         <a href="#rid23">
          23-26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infections
         </strong>
         – Direct lung injury due to pulmonary infection is a common cause of ARDS and likely contributes to AE-IPF as well. Lower respiratory viral infections are present in a significant minority of cases of AE-IPF [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microaspiration of gastric contents
         </strong>
         – Microaspiration of gastric contents is a proposed risk factor for exacerbations and progression of IPF. There is weak evidence for a potential benefit from pharmacologic treatment [
         <a href="#rid28">
          28
         </a>
         ], but guidelines argue against empiric treatment in asymptomatic patients [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Empiric treatment for asymptomatic gastroesophageal reflux'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery and thoracic procedures
         </strong>
         – Thoracic procedures, such as surgical lung biopsy, lung cancer resection, and bronchoscopy, have been associated with the development of IPF exacerbations [
         <a href="#rid30">
          30-34
         </a>
         ]. Nonthoracic surgical procedures have also been implicated in development of exacerbations [
         <a href="#rid33">
          33
         </a>
         ]. Potential mechanisms include administration of high concentrations of oxygen and volutrauma or barotrauma during mechanical ventilation. However, a causal relationship between IPF exacerbations and procedures is difficult to ascertain due to the retrospective analysis of the studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advanced lung disease
         </strong>
         – Clinical factors of physiologically advanced IPF are associated with increased rates of AE, including: lower FVC, diffusing capacity of the lung for carbon monoxide (DLCO), and six-minute walk distance [
         <a href="#rid25">
          25,35,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – A number of other potential contributors have been implicated, such as evidence of pulmonary hypertension, higher body mass index, coronary artery disease, and treatment with immunosuppressive therapy [
         <a href="#rid10">
          10,36-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H706062534">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with IPF, an acute exacerbation typically presents with shortness of breath or worsening exercise tolerance that develop over days to weeks, but generally less than one month [
         <a href="#rid12">
          12,39
         </a>
         ]. In a small series of 11 patients, the time from onset of symptoms to hospital admission averaged approximately 13 days [
         <a href="#rid13">
          13
         </a>
         ]. Cough (with or without sputum production) is common; fever and flu-like symptoms may also be present.
        </p>
        <p>
         On physical examination, the patient may be tachypneic and will typically have bibasilar crackles consistent with the underlying diagnosis of IPF.
        </p>
        <p>
         Patients typically demonstrate impaired gas exchange, as evidenced by an arterial oxygen tension to fraction of inspired oxygen ratio (PaO
         <sub>
          2
         </sub>
         /FiO
         <sub>
          2
         </sub>
         ) of less than 225 mmHg or a decrease in the PaO
         <sub>
          2
         </sub>
         of 10 mmHg or more from baseline.
        </p>
        <p>
         As noted above, high-resolution computed tomography (HRCT) reveals bilateral ground glass or consolidative opacities superimposed on a background of typical HRCT features of IPF (eg, bibasilar reticular opacities, honeycomb changes, traction bronchiectasis). (See
         <a class="local">
          'Definition'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis", section on 'Chest imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H496469754">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presenting symptoms and signs of AE-IPF are not specific, and the evaluation should exclude alternate diagnoses (eg, pneumothorax, heart failure, venous thromboembolism) and identify potential triggers of AE-IPF, such as lung infection or a recent lung procedure.
        </p>
        <p class="headingAnchor" id="H2542771639">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no laboratory studies specific to the diagnosis of AE in IPF. As identification and management of comorbidities is fundamental to the management of these patients, careful evaluation for potential contributing or alternate diagnoses is critical. We typically obtain complete blood and differential cell counts, brain natriuretic peptide, serial troponin tests, procalcitonin, and sensitive D-dimer. The role of serum markers of inflammation and lung injury is unclear [
         <a href="#rid12">
          12,40
         </a>
         ]. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are nonspecific and have not proved helpful.
        </p>
        <p>
         Testing for potential lung infection typically includes blood cultures, urinary antigen assays for
         <em>
          Streptococcus pneumoniae
         </em>
         and
         <em>
          Legionella
         </em>
         , rapid influenza antigen test on respiratory secretions (in the appropriate season), and multiplex polymerase chain reaction (PCR) test for respiratory viruses [
         <a href="#rid27">
          27,41,42
         </a>
         ]. The rapid influenza tests have a specificity of &gt;95 percent, but the sensitivity is only about 50 to 60 percent, so a negative result does not rule out influenza [
         <a href="#rid43">
          43,44
         </a>
         ]. Real-time reverse-transcriptase PCR is the test of choice to diagnose influenza but requires a laboratory and a laboratory technician. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Of note, troponins, while typically used to look for evidence of an acute myocardial infarction, can be elevated in patients with a moderately large pulmonary embolism. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3722378524">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first step is often a conventional chest radiograph to exclude a pneumothorax or other abnormality that requires immediate attention. High-resolution computed tomography (HRCT), with or without a rule-out pulmonary embolism protocol, is necessary for appropriate classification of the parenchymal abnormalities [
         <a href="#rid12">
          12
         </a>
         ]. We have a very low threshold to perform CT pulmonary angiogram to exclude pulmonary embolism due to the significantly increased risk of venous thromboembolism in IPF [
         <a href="#rid45">
          45-47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         HRCT in patients with an AE-IPF will demonstrate typical chronic background findings of a usual interstitial pneumonia pattern (eg, reticulation, traction bronchiectasis, honeycomb changes) in combination with more acute abnormalities of increased ground glass opacity and/or consolidation. Three HRCT distribution patterns have been described: peripheral, multifocal, and diffuse [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
         For patients who are unable to undergo CT pulmonary angiography due to kidney disease, an alternative approach is to obtain ventilation-perfusion (V/Q) scanning, possibly with lower extremity compressive ultrasonography if the V/Q scan is indeterminate. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Ventilation perfusion scan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3925744567">
         <span class="h2">
          Flexible bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Flexible bronchoscopy with bronchoalveolar lavage (BAL) is part of our standard evaluation of patients with AE-IPF, as long as the patient is clinically able to tolerate the procedure. The main role is to identify and characterize any infection or malignancy. When performing a BAL for this purpose, we select a subsegment that appears to be involved based on the HRCT findings. BAL samples are sent for a broad spectrum of microbiologic tests, including stains and cultures for bacteria, mycobacteria, and fungi, as well as multiplex PCR testing for respiratory viruses. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         .)
        </p>
        <p>
         Transbronchial biopsies are generally not helpful due to their small size and are not part of our standard work-up [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H575174354">
         <span class="h2">
          Avoidance of surgical lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical lung biopsy is of minimal value in AE-IPF. Given the high surgical risk in this patient population, we do not recommend it [
         <a href="#rid20">
          20,49,50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Interstitial lung disease presenting with acute respiratory failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H683178067">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of AE-IPF is generally made in a patient with known or concurrently diagnosed IPF and the following features [
         <a href="#rid12">
          12
         </a>
         ] (see
         <a class="local">
          'Definition'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An acute, clinically significant respiratory deterioration typically &lt;1 month in duration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-resolution computed tomography (HRCT) demonstrating new bilateral ground-glass opacification and/or consolidation superimposed on a background of findings consistent with usual interstitial pneumonia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of heart failure and fluid overload as significant contributors to the deterioration
        </p>
        <p>
        </p>
        <p>
         Flexible bronchoscopy with bronchoalveolar lavage (BAL) is used to identify infectious agents and exclude malignancy. While the 2007 criteria for AE-IPF required the exclusion of infection, the 2016 criteria do not exclude potential triggers, such as infection, lung procedures/operations, drug toxicity, and aspiration [
         <a href="#rid11">
          11,12
         </a>
         ]. These potential triggers should be noted, but do not exclude AE-IPF.
        </p>
        <p class="headingAnchor" id="H2740668081">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of AE-IPF includes venous thromboembolism, infection, and heart failure. A pneumothorax can complicate IPF, but would usually be recognized on a conventional chest radiograph. Pulmonary hypertension developing as a consequence of IPF is also in the differential diagnosis of worsening dyspnea, but would not have the new radiographic opacities associated with AE-IPF.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venous thromboembolism
         </strong>
         – IPF is associated with a significantly increased risk of venous thromboembolism (VTE) [
         <a href="#rid45">
          45-47
         </a>
         ]. The suspicion for VTE is increased in patients with obesity, immobilization, malignancy, and prior or family history of VTE. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – For patients who can tolerate the procedure, our standard practice is to perform a full investigation for potential lung infection and to initiate empiric antibiotics for pneumonia while studies are pending, as described (see
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above). The choice of antibiotics for community-acquired pneumonia is described separately. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart failure
         </strong>
         – Given the average age of individuals with IPF, careful cardiac assessment for heart failure or myocardial infarction is appropriate. We typically begin with serial troponin, brain natriuretic peptide (BNP), and an electrocardiogram. An echocardiogram is not typically a first line assessment, but may be useful to evaluate for heart failure in a subset of patients, such as those with extrathoracic clinical features of heart failure or an elevated BNP. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         – Pulmonary hypertension (group 3), a well-known complication of IPF, also presents with worsening dyspnea, but without increased radiographic opacities. The diagnosis is often suspected in patients with worsening gas transfer without evidence of worsening interstitial lung disease. Plasma BNP is often increased, and Doppler echocardiography can provide an estimate of pulmonary artery systolic pressure. A firm diagnosis requires right heart catheterization. (See
         <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1221394245">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal therapy for AE-IPF has not been established. All patients require supportive care to relieve hypoxemia and alleviate symptoms of shortness of breath and cough. Most experts, including ourselves, administer systemic glucocorticoids, although randomized trial data are lacking.
        </p>
        <p>
         Other therapies to treat AE-IPF have been reported in case series, but the study design and small numbers limit clear conclusions regarding efficacy and safety of these interventions and emphasize the need for randomized trials [
         <a href="#rid12">
          12
         </a>
         ]. Preliminary studies with these agents are described below. (See
         <a class="local">
          'Investigational approaches'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4180677765">
         <span class="h2">
          Supportive measures
         </span>
        </p>
        <p class="headingAnchor" id="H902188237">
         <span class="h3">
          Routine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive measures for all patients with AE-IPF include provision of supplemental oxygen and relief of dyspnea. Standard measures for prevention of VTE and stress gastropathy are prudent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxygenation
         </strong>
         – Patients with AE-IPF often have a high oxygen requirement to maintain a pulse oxygen saturation above 88 percent and their high inspiratory flow rate may make oxygenation with standard low-flow nasal cannula difficult.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         High-flow oxygen therapy by nasal cannula may be a reasonable alternative for patients with acute hypoxemic respiratory failure
         <strong>
          without
         </strong>
         hypercapnia who are not able to achieve an adequate SpO
         <sub>
          2
         </sub>
         with low-flow oxygen. (See
         <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">
          "Continuous oxygen delivery systems for the acute care of infants, children, and adults", section on 'Nasal cannula'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relief of dyspnea
         </strong>
         – For some patients, treating hypoxemia with supplemental oxygen is sufficient to treat dyspnea, but dyspnea due to IPF may be refractory. Palliative care strategies may help alleviate dyspnea, as described below. (See
         <a class="local">
          'Palliative care'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of venous thromboembolism
         </strong>
         – Patients who are hospitalized with an AE-IPF are at increased risk of venous thromboembolism. Routine measures used to prevent VTE in hospitalized patients should be employed. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-acid therapy
         </strong>
         – As noted above, acid aspiration has been implicated as a potential contributor to AE-IPF based on analysis of data from the placebo arms of three randomized trials [
         <a href="#rid28">
          28
         </a>
         ]. A randomized trial of laparoscopic Nissen fundoplication in 58 individuals with stable IPF and abnormal acid gastroesophageal reflux did not decrease rates of acute exacerbation [
         <a href="#rid51">
          51
         </a>
         ]. Data are not available regarding a potential role for anti-acid therapy in the context of AE-IPF. We typically continue any anti-acid therapy that the patient has been taking. For patients not on anti-acid therapy at the time of admission, we usually follow guidelines for stress ulcer prophylaxis. (See
         <a class="local">
          'Pathophysiology and risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">
          "Stress ulcers in the intensive care unit: Diagnosis, management, and prevention", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1199663079">
         <span class="h3">
          Mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role and efficacy of noninvasive positive pressure ventilation and low tidal volume mechanical ventilation have not been formally studied in AE-IPF. We believe that mechanical ventilation is of limited value in the IPF patient with an acute deterioration without a defined treatable trigger, based on high mortality rates and the poor outcomes reported for mechanical ventilation in IPF [
         <a href="#rid52">
          52
         </a>
         ]. Thus, we make every effort to communicate the limitations of mechanical ventilation to the patient and their family. (See
         <a class="local">
          'Palliative care'
         </a>
         below.)
        </p>
        <p>
         Multiple cohorts demonstrate poor short-term prognosis for patients with AE-IPF admitted to the ICU and/or mechanically ventilated [
         <a href="#rid52">
          52-55
         </a>
         ]. In a large database study of patients with IPF who were hospitalized in the United States, 1703 patients were treated with mechanical ventilation and 778 were treated with noninvasive ventilation [
         <a href="#rid52">
          52
         </a>
         ]. Among those with a primary diagnosis of IPF, the mortality rate was 49 percent regardless of the type of ventilatory support. In other studies, mortality has reached 96 percent [
         <a href="#rid56">
          56
         </a>
         ]. If the patient chooses to pursue a trial of invasive mechanical ventilation, it may be helpful to outline parameters for discontinuing ventilatory support should the patient fail to improve.
        </p>
        <p>
         Hopefully, all patients with IPF will have had the opportunity to have discussions about goals of care with their physicians prior to the onset of an AE, so the patient, family, and clinician can make decisions that are in concert with the patient's values and preferences. (See
         <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">
          "Palliative care for adults with nonmalignant chronic lung disease", section on 'Advance care planning'
         </a>
         and
         <a class="local">
          'Palliative care'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2062133372">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The international evidence-based guidelines for AE-IPF suggest administering systemic glucocorticoids in the majority of patients with AE-IPF [
         <a href="#rid56">
          56
         </a>
         ]. No clinical trials have been performed, so the guidelines put a high value on anecdotal reports of benefit. We typically treat AE-IPF with glucocorticoids in the range of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg per day orally to
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         1 gram per day intravenously for three days followed by a taper, based on severity of disease and response to therapy. For those individuals who appear to a have a clinical response to glucocorticoids, we will typically taper them slowly over the course of weeks to months ensuring there is no recurrence with close follow up.
        </p>
        <p>
         Multiple reports outline glucocorticoid use as monotherapy [
         <a href="#rid12">
          12,53,57-59
         </a>
         ]. On the other hand, some investigators have reported an immunosuppression-free approach with similar outcomes in AE [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         While autopsy and biopsy data from this cohort typically demonstrate usual interstitial pneumonia with diffuse alveolar damage (DAD), a few reports describe concomitant organizing pneumonia, which may respond to glucocorticoids. Further, one may hypothesize that activation of the immune response plays a role in the acute deterioration of these patients.
        </p>
        <p class="headingAnchor" id="H3354978921">
         <span class="h2">
          Antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Broad-spectrum antibiotics are typically initiated upon presentation as the radiographic findings overlap with pneumonia. Given the severity of disease and poor prognosis, many experts complete a seven day course even if all cultures are negative. Our approach is to cover broadly at presentation, including atypical coverage. If cultures/testing identify a specific pathogen, we narrow the coverage appropriately. For those without a pathogen, we limit the antibiotics to a seven-day course.
        </p>
        <p>
         In addition to broad-spectrum antibiotics, we support antiviral treatment for proven viral respiratory infections. Patients with IPF are designated by the United States Centers for Disease Control and Prevention (CDC) as persons at risk for severe COVID-19 (coronavirus disease 2019)  (
         <a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">
          table 1
         </a>
         ), and therefore qualify for prioritized access to antiviral therapies including nirmatrelvir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         and
         <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">
          remdesivir
         </a>
         . Neuraminidase inhibitors should be used in patients with influenza infection.
        </p>
        <p>
         Biologic markers, such as procalcitonin and C-reactive protein (CRP), are sometimes used to try to distinguish between bacterial and nonbacterial causes of pneumonia. One randomized trial evaluated the use of procalcitonin (PCT)-guided antibiotic treatment versus standard clinician determined care in 61 patients with AE-IPF [
         <a href="#rid61">
          61
         </a>
         ]. This trial demonstrated shorter duration of antibiotic use with PCT monitoring while the duration of mechanical ventilation and overall mortality were unchanged [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">
          "Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Serum biomarkers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1155803851">
         <span class="h2">
          Nintedanib and pirfenidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accumulating data suggest that the antifibrotic agents,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         , help prevent AEs [
         <a href="#rid8">
          8,12,62,63
         </a>
         ]. Unfortunately, the value of adding or continuing nintedanib or pirfenidone during an AE remains unknown. Our practice is to continue the patient on their established therapy. For patients not on one of these agents, it may be reasonable to initiate one of the antifibrotic agents after resolution of the AE. The effect of nintedanib and pirfenidone on disease progression and mortality is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Medical therapies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1849375287">
         <span class="h2">
          Lung transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung transplantation provides a survival benefit for selected patients who have IPF, but are not in the midst of an AE. For those with an acute deterioration, perioperative risks of transplantation are clearly greater. For individuals with AE-IPF transplanted in the context of mechanical ventilation or ICU stay, both one- and three-year survivals after lung transplantation appear decreased compared with stable patients undergoing elective transplantation [
         <a href="#rid64">
          64
         </a>
         ]. In contrast, 25 patients with an AE-interstitial lung disease (ILD; not limited to IPF) who underwent lung transplant had similar one-year survival compared with 67 patients with stable ILD transplanted during the same period (96 percent versus 92.5 percent, respectively) [
         <a href="#rid65">
          65
         </a>
         ]. In the latter study, the majority of patients were supported with high flow nasal cannula rather than invasive mechanical ventilation; only one patient was on extracorporeal membrane oxygenation (ECMO) at the time of transplant.
        </p>
        <p>
         For individuals who have yet to undergo assessment by a transplant center, urgent lung transplantation may not be available due to limited time and resources, and would depend on discussions with regional lung transplant center. Rarely, in patients who have already been listed for transplantation and are hospitalized at a transplant center, extracorporeal membrane oxygenation can be used as a bridge to transplant.
        </p>
        <p>
         The best recommendation remains that patients with IPF who are potential candidates for lung transplantation should be referred for evaluation early in the course of their disease, so that full assessments may be made while the patient is stable. (See
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1698435423">
         <span class="h2">
          Palliative care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the poor prognosis of patients with AE-IPF, palliative care consultation to provide relief from symptoms and stress for the patient and family is vital. We routinely use palliative care services as an extra layer of psychosocial support for these patients. (See
         <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">
          "Palliative care for adults with nonmalignant chronic lung disease"
         </a>
         .)
        </p>
        <p>
         Palliation of dyspnea is an important component of end-of-life care. Palliative strategies to reduce dyspnea in an individual patient may include relaxation techniques, facial cooling with a fan, opiates, benzodiazepines, and sometimes noninvasive ventilation. A few studies have suggested a role for noninvasive ventilation to reduce dyspnea, although this requires a clear discussion of goals of care, especially in patients who prefer not to pursue life-prolonging treatments. Palliation of dyspnea is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care"
         </a>
         .)
        </p>
        <p>
         Cough can also be a troubling symptom that may benefit from a palliative approach. (See
         <a class="medical medical_review" href="/z/d/html/83242.html" rel="external">
          "Palliative care: Overview of cough, stridor, and hemoptysis in adults", section on 'Cough'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3877629871">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AE-IPF portends a poor prognosis for patients with this progressive fibrotic lung disease. AE precedes approximately 40 percent of IPF deaths [
         <a href="#rid36">
          36,66
         </a>
         ], and the median survival following an AE is approximately three to four months [
         <a href="#rid14">
          14,25
         </a>
         ]. More severe disease (lower baseline forced vital capacity and diffusing capacity of the lung for carbon monoxide) as well as more extensive computerized tomography findings and worse oxygenation at presentation are associated with worse outcome [
         <a href="#rid48">
          48,67
         </a>
         ]. Respiratory failure resulting in the need for mechanical ventilation or noninvasive ventilation has an extremely poor prognosis [
         <a href="#rid52">
          52-55
         </a>
         ].
        </p>
        <p>
         Serum markers such as lactate dehydrogenase, Kerbs von Lungren 6 antigen, neutrophil elastase, circulating fibrocytes, and antiheat shock protein antibodies may have prognostic value but are not recommended for routine clinical use until more studies validate their usefulness [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H197211930">
         <span class="h1">
          AGENTS WITHOUT BENEFIT
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclophosphamide
         </strong>
         – A phase 3 multicenter randomized trial (EXAFIP) evaluated the efficacy of adding
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (600 mg/m
         <sup>
          2
         </sup>
         intravenous pulses) or placebo to high-dose glucocorticoids in 119 patients with AE-IPF [
         <a href="#rid70">
          70
         </a>
         ]. The three-month mortality was higher in the cyclophosphamide group than in the control group even after adjusting for IPF severity. The rate of infectious complications was similar between the groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3423203152">
         <span class="h1">
          INVESTIGATIONAL APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational studies have examined the following treatments, sometimes using historical or parallel untreated controls. These interventions require additional study prior to widespread implementation. Information about ongoing clinical trials can be obtained at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=110885" target="_blank">
          clinicaltrials.gov
         </a>
         . It is hoped that the revised definition of AE-IPF will enable researchers to test novel hypotheses of the pathophysiologic mechanisms and also novel approaches to detection and treatment in well-designed clinical trials [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclosporine
         </strong>
         – Small retrospective series have suggested a slight survival benefit to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         added to systemic glucocorticoids compared with those managed without cyclosporine [
         <a href="#rid71">
          71-73
         </a>
         ]. However, a large retrospective series (7989 patients) found no mortality benefit with the addition of cyclosporine to high-dose
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         in patients with acute exacerbations of IPF [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
         <strong>
          with therapeutic plasma exchange
         </strong>
         – In a small series of seven critically-ill patients with AE-IPF, therapeutic plasma exchange (TPE) was performed on day one and four to eight additional times, and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was administered twice (roughly on days 5 and 15) [
         <a href="#rid75">
          75
         </a>
         ]. Pulse
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         was administered on day 1 followed by a
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper over 3 weeks. An additional four patients received TPE, rituximab, glucocorticoids, and also intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         0.5 mg/kg/day on days 16 to 19. One year survival was 46 +/-15 percent compared with 5 percent among the historical controls.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tacrolimus
         </strong>
         – Fifteen patients with AE-IPF were treated with
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         pulse therapy with (n = 5) or without (n = 10) oral
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ]. Four patients in the tacrolimus group survived compared with one of the non-tacrolimus group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemoperfusion with polymyxin-B immobilized fiber
         </strong>
         – Hemoperfusion with polymyxin-B immobilized fiber was developed to remove endotoxin, but may also remove cytokines that contribute to lung injury [
         <a href="#rid77">
          77-79
         </a>
         ]. In a retrospective series of 160 patients with AE-IPF who underwent this therapy, oxygenation improved after the second treatment [
         <a href="#rid77">
          77
         </a>
         ]. The one and three month survival rates were 70 and 34 percent, respectively. The majority of the patients also received high dose systemic glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous recombinant thrombomodulin
         </strong>
         – One hypothesis is that disordered coagulation and fibrinolysis contribute to the pathogenesis of AE-IPF. Recombinant human soluble thrombomodulin alpha (rhTM) has anti-inflammatory, anticoagulant, and antifibrinolytic properties that might ameliorate these processes. While preliminary studies suggested a beneficial effect in AE-IPF [
         <a href="#rid80">
          80-82
         </a>
         ], rhTM did not improve survival at 90 days in a randomized trial with 82 participants [
         <a href="#rid83">
          83
         </a>
         ]. Bleeding adverse events were higher with rhTM than placebo. The results of this trial suggest that rhTM should not be used for the treatment of AE-IPF.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3028432559">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2964290815">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (See
         <a class="medical medical_basics" href="/z/d/html/83031.html" rel="external">
          "Patient education: Idiopathic pulmonary fibrosis (The Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2545395285">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – The exact definition of AE-IPF is a work in progress, but the following features are proposed (see
         <a class="local">
          'Definition'
         </a>
         above): a known diagnosis of IPF (diagnosis may be made at the time of acute respiratory deterioration); acute worsening (typically less than one month's duration); CT of the chest with new bilateral ground-glass opacification and/or consolidation superimposed on a background of findings consistent with usual interstitial pneumonia (bibasilar reticular opacities associated with honeycomb changes and traction bronchiectasis); and heart failure or fluid overload does not fully explain the worsening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – AE-IPF likely arises from maladaptive responses to direct lung injury. Known and suspected risk factors include respiratory infections, aspiration, mechanical ventilation, and immunosuppressive therapy. (See
         <a class="local">
          'Pathophysiology and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Evaluation of patients presenting with AE should focus on identifying contributing or alternate causes of decline, such as venous thromboembolism (VTE), infection, and heart failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory testing
         </strong>
         typically involves obtaining a complete blood count and differential cell count, brain natriuretic peptide, serial troponin tests, procalcitonin, and sensitive D-dimer. For potential lung infection, we perform blood cultures, urinary antigen assays for
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          Legionella
         </em>
         , rapid influenza antigen test on respiratory secretions (in the appropriate season), and polymerase chain reaction (PCR) tests for respiratory viruses, including COVID-19. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging
         </strong>
         should include high-resolution computed tomography (HRCT) in all patients. We have a low threshold for obtaining a CT pulmonary angiogram to rule out pulmonary embolism. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bronchoscopy
         </strong>
         with bronchoalveolar lavage (BAL) is often helpful to evaluate for lung infection if the patient will tolerate the procedure. Transbronchial biopsies or open lung biopsies are not indicated. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Supportive Measures
         </strong>
         – Initial management of AE in all patients should consist of supplemental oxygen and palliation of shortness of breath. Current evidence-based guidelines and our own practice advise against the use of mechanical ventilation given the extremely poor prognosis. Early discussions about goals of care are appropriate, and decisions should be made on an individual basis. (See
         <a class="local">
          'Mechanical ventilation'
         </a>
         above and
         <a class="local">
          'Palliative care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – We suggest a trial of empiric treatment with systemic glucocorticoids in patients with AE-IPF (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The usual dose ranges from
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg per day orally to
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         1 gram per day for three days followed by a prednisone taper, based on severity of disease and response to therapy. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotics
         </strong>
         – We initiate broad-spectrum antibiotics, including atypical coverage, upon presentation. Antibiotic treatment is tailored if an organism is identified and we typically continue antibiotics for a seven-day course. (See
         <a class="local">
          'Antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antifibrotics
         </strong>
         – There are no data examining a role for
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         or
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         during an AE-IPF. Our practice is to continue patients on their baseline regimen but not to initiate de novo therapy during the acute exacerbation. (See
         <a class="local">
          'Nintedanib and pirfenidone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lung transplantation
         </strong>
         – Lung transplantation for AE-IPF is occasionally possible in patients who have previously undergone transplant evaluation. However, it carries significant risk and is usually not feasible in the midst of an AE-IPF. (See
         <a class="local">
          'Lung transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Palliative care
         </strong>
         – Given the poor prognosis of patients with AE-IPF, palliative care consultation to provide relief from symptoms and stress for the patient and family is vital. We routinely use palliative care services as an extra layer of psychosocial support for these patients. (See
         <a class="local">
          'Palliative care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – AE-IPF precedes approximately 40 percent of IPF deaths and portends a poor prognosis. The median survival following an AE-IPF is approximately three to four months. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162:2213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival. Thorax 2007; 62:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Andrade J, Schwarz M, Collard HR, et al. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. Chest 2015; 148:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir Med 2014; 108:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson ND, Frutos-Vivar F, Esteban A, et al. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit Care Med 2005; 33:2228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008; 32:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oda K, Ishimoto H, Yamada S, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res 2014; 15:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128:3310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson O, Diebold D, Fan D, et al. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One 2008; 3:e3220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014; 124:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J 2014; 43:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomioka H, Sakurai T, Hashimoto K, Iwasaki H. Acute exacerbation of idiopathic pulmonary fibrosis: role of Chlamydophila pneumoniae infection. Respirology 2007; 12:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:1698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiwatari N, Shimura S, Takishima T, Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 1994; 174:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bando M, Ohno S, Hosono T, et al. Risk of Acute Exacerbation After Video-assisted Thoracoscopic Lung Biopsy for Interstitial Lung Disease. J Bronchology Interv Pulmonol 2009; 16:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bando T, Date H. [Surgical treatment of lung cancer in patients with pulmonary fibrosis]. Kyobu Geka 2012; 65:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung 2012; 190:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto S, Homma S, Mun M, et al. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med 2011; 50:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondoh Y, Taniguchi H, Ebina M, et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan. Respir Investig 2015; 53:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakugawa T, Sakamoto N, Sato S, et al. Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respir Res 2016; 17:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon-Blancal V, Freynet O, Nunes H, et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration 2012; 83:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299:L3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ushiki A, Yamazaki Y, Hama M, et al. Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. Respir Investig 2014; 52:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huie TJ, Olson AL, Cosgrove GP, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010; 15:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prechter GC, Gerhard AK. Postinfluenza toxic shock syndrome. Chest 1989; 95:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 181:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011. Am J Respir Crit Care Med 2016; 193:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson JP, McKeever TM, Fogarty AW, et al. Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008. Eur Respir J 2016; 48:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med 2018; 6:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis. Respir Med 2016; 111:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudry S, Vincent F, Rabbat A, et al. Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia. J Thorac Cardiovasc Surg 2014; 147:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med 2008; 102:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki H, Sekine Y, Yoshida S, et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 2011; 41:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tachikawa R, Tomii K, Ueda H, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration 2012; 83:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akira M, Hamada H, Sakatani M, et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papiris SA, Kagouridis K, Kolilekas L, et al. Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC Pulm Med 2015; 15:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int J Med Sci 2013; 10:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest 2021; 160:1751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dotan Y, Vaidy A, Shapiro WB, et al. Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest 2018; 154:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chizinga M, Machuca TN, Shahmohammadi A, et al. Lung transplantation for acute exacerbation of interstitial lung disease. Thorax 2022; 77:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujimoto K, Taniguchi H, Johkoh T, et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol 2012; 22:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naccache JM, Montil M, Cadranel J, et al. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulm Med 2019; 19:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005; 44:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto S, Homma S, Miyamoto A, et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010; 49:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inase N, Sawada M, Ohtani Y, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003; 42:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aso S, Matsui H, Fushimi K, Yasunaga H. Effect of cyclosporine A on mortality after acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis 2018; 10:5275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donahoe M, Valentine VG, Chien N, et al. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS One 2015; 10:e0127771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horita N, Akahane M, Okada Y, et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2011; 50:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe S, Azuma A, Mukae H, et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med 2012; 51:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tachibana K, Inoue Y, Nishiyama A, et al. Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oishi K, Mimura-Kimura Y, Miyasho T, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine 2013; 61:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isshiki T, Sakamoto S, Kinoshita A, et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration 2015; 89:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsushima K, Yamaguchi K, Kono Y, et al. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study. Pulm Pharmacol Ther 2014; 29:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kataoka K, Taniguchi H, Kondoh Y, et al. Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest 2015; 148:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med 2020; 201:1110.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 110885 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445300" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11866008" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical significance of histological classification of idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11587991" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112140" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16769717" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19570573" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836312" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836310" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836309" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22607134" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17585107" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acute exacerbations of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27299520" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16387947" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26111071" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24440032" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16215375" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256070" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25176016" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16304277" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18795102" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fibrotic myofibroblasts manifest genome-wide derangements of translational control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24590289" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fibrotic extracellular matrix activates a profibrotic positive feedback loop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24176998" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22183478" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595144" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17875058" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Acute exacerbation of idiopathic pulmonary fibrosis: role of Chlamydophila pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21471095" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24429201" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35486072" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7732520" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23168584" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk of Acute Exacerbation After Video-assisted Thoracoscopic Lung Biopsy for Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22868434" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : [Surgical treatment of lung cancer in patients with pulmonary fibrosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22543997" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21245629" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26521104" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21319592" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Risk factors of acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22135282" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27401332" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21860222" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20418386" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24388373" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20546190" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888586" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651040" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Postinfluenza toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755924" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20167844" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21737559" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18451320" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646481" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27660509" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30100404" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26733227" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15045042" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23968871" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635345" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21471066" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21748606" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21912082" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8976924" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26666385" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23781136" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21992121" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34217681" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29966665" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34226204" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Lung transplantation for acute exacerbation of interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162152" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21822949" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19151190" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23262513" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30971235" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16357451" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20075573" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12879947" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30416775" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effect of cyclosporine A on mortality after acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26083430" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21297319" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728479" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22117502" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021430" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25659984" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836398" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25811735" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31917621" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
